抗癌抗体药物偶联物相关的眼部不良事件:聚焦病理生理与管理策略
本综述概述已批准和在研抗体药物偶联物(ADC)抗癌治疗可能出现的眼部不良事件(AE),包括干眼、结膜炎、畏光、视物模糊和角膜异常,并讨论潜在机制(多归因于脱靶效应)。已批准ADC的产品标签包含药物特异性剂量调整和眼部AE管理指导,但有效减轻眼部AE的策略数据有限;多数眼部AE可通过剂量调整或支持治疗逆转。眼科医生在与肿瘤科医生协作中,对早期识别、减轻和管理治疗相关眼部AE起重要作用。
要点
- ADC抗癌治疗相关眼部AE包括干眼、结膜炎、畏光、视物模糊和角膜异常,多数归因于脱靶效应。
- 已批准ADC产品标签含药物特异性剂量调整和眼部AE管理指导,但有效减轻眼部AE的策略数据有限。
- 多数眼部AE可通过剂量调整或支持治疗逆转,眼科医生需监测接受ADC治疗患者的眼部体征和症状。
核心结论
- 多数ADC相关眼部AE可通过剂量调整或支持治疗逆转,眼科医生在与肿瘤科医生协作中对早期识别、减轻和管理治疗相关眼部AE起重要作用。
研究设计与样本
- 本综述概述已批准和在研ADC抗癌治疗可能出现的眼部AE、潜在机制及眼科医生相关的临床管理实践。
主要发现
- ADC抗癌治疗可能伴随干眼、结膜炎、畏光、视物模糊和角膜异常等眼部AE。
- ADC相关眼部AE的病理生理尚未完全阐明,多数眼部AE归因于脱靶效应。
- 已批准ADC的产品标签包含药物特异性剂量调整和管理眼部AE的指导,但有效减轻和缓解眼部AE的策略数据有限。
- 多数眼部AE可通过剂量调整或支持治疗逆转。
临床怎么用
- 眼科医生应监测接受ADC治疗患者的眼部体征和症状,以便早期发现ADC相关眼部AE并及时给予适当治疗。
- 眼科医生需提高认识,以识别治疗相关眼部AE,并与肿瘤科医生协作作为患者癌症护理团队的一部分提供有效管理。
- 眼科医生在与肿瘤科医生协作中,通过协助及时识别、减轻和管理治疗相关眼部AE,在癌症患者护理中起重要作用。
局限性
- ADC相关眼部AE的病理生理尚未完全阐明。
- 有效减轻和缓解眼部AE的策略数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-drug conjugates (ADCs) are designed to maximize cancer cell death with lower cytotoxicity toward noncancerous cells and are an increasingly valuable option for targeted cancer therapies. However, anticancer treatment with ADCs may be associated with ocular adverse events (AEs) such as dry eye, conjunctivitis, photophobia, blurred vision, and corneal abnormalities. While the pathophysiology of ADC-related ocular AEs has not been fully elucidated, most ocular AEs are attributed to off-target effects. Product labelling for approved ADCs includes drug-specific guidance for dose modification and management of ocular AEs; however, limited data are available regarding effective strategies to minimize and mitigate ocular AEs. Overall, the majority of ocular AEs are reversible through dose modification or supportive care. Eye care providers play key roles in monitoring patients receiving ADC therapy for ocular signs and symptoms to allow for the early detection of ADC-related ocular AEs and to ensure the timely administration of appropriate treatment. Therefore, awareness is needed to help ophthalmologists to identify treatment-related ocular AEs and provide effective management in collaboration with oncologists as part of the patient's cancer care team. This review provides an overview of ocular AEs that may occur with approved and investigational ADC anticancer treatments, including potential underlying mechanisms for ADC-related ocular AEs. It also discusses clinical management practices relevant to ophthalmologists for prevention, monitoring, and management of ADC-related ocular AEs. In collaboration with oncologists, ophthalmologists play a vital role in caring for patients with cancer by assisting with the prompt recognition, mitigation, and management of treatment-related ocular AEs.
引用
- Gabison EE, Rousseau A, Labetoulle M, et al. Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies. Prog Retin Eye Res. 2024. PMID: 39303762. doi:10.1016/j.preteyeres.2024.101302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。